within Pharmacolibrary.Drugs.ATC.B;

model B03BA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.007500000000000001,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Hydroxocobalamin is a form of vitamin B12, used primarily for the treatment of vitamin B12 deficiency and as an antidote to cyanide poisoning. In combination products (ATC code B03BA53), it may be co-formulated with other vitamins or minerals for parenteral supplementation, but such combinations are not widely approved or available in all countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for hydroxocobalamin, combinations (ATC B03BA53) have not been specifically published. The following estimates are based on the pharmacokinetics of hydroxocobalamin monotherapy in healthy adults after intravenous administration.</p><h4>References</h4><ol><li><p>Thompson, JP, &amp; Marrs, TC (2012). Hydroxocobalamin in cyanide poisoning. <i>Clinical toxicology (Philadelphia, Pa.)</i> 50(10) 875–885. DOI:<a href=&quot;https://doi.org/10.3109/15563650.2012.742197&quot;>10.3109/15563650.2012.742197</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23163594/&quot;>https://pubmed.ncbi.nlm.nih.gov/23163594</a></p></li><li><p>Shepherd, G, &amp; Velez, LI (2008). Role of hydroxocobalamin in acute cyanide poisoning. <i>The Annals of pharmacotherapy</i> 42(5) 661–669. DOI:<a href=&quot;https://doi.org/10.1345/aph.1K559&quot;>10.1345/aph.1K559</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18397973/&quot;>https://pubmed.ncbi.nlm.nih.gov/18397973</a></p></li><li><p>Forsyth, JC, et al., &amp; Hall, AH (1993). Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. <i>Journal of toxicology. Clinical toxicology</i> 31(2) 277–294. DOI:<a href=&quot;https://doi.org/10.3109/15563659309000395&quot;>10.3109/15563659309000395</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8492341/&quot;>https://pubmed.ncbi.nlm.nih.gov/8492341</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03BA53;
